Analysts expect Motif Bio plc (NASDAQ:MTFB) to report $-0.45 EPS on April, 9. The stock decreased 5.92% or $0.1 during the last trading session, reaching $1.59. About 203,040 shares traded or 22.06% up from the average. Motif Bio plc (NASDAQ:MTFB) has declined 78.75% since March 17, 2018 and is downtrending. It has underperformed by 83.12% the S&P500.
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company has market cap of $22.49 million. The firm develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. It currently has negative earnings. The Company’s lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
More notable recent Motif Bio plc (NASDAQ:MTFB) news were published by: Seekingalpha.com which released: “Microcaps dominate midday movers – Seeking Alpha” on February 19, 2019, also Benzinga.com with their article: “Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering – Benzinga” published on February 20, 2019, Benzinga.com published: “The Daily Biotech Pulse: BioMarin (NASDAQ:BMRN) Slips On Earnings, TherapeuticsMD (NASDAQ:TXMD) Posts In-Line Results, Orchard (NASDAQ:ORTX) To Present Immunodeficiency Drug Data – Benzinga” on February 22, 2019. More interesting news about Motif Bio plc (NASDAQ:MTFB) were released by: Nasdaq.com and their article: “Health Care Sector Update for 02/14/2019: MTFB, MDGS, INO, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on February 14, 2019 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare – Seeking Alpha” with publication date: February 08, 2019.